Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Department of Medical Physiology, Urmia University of Medical Sciences, Urmia, Iran.
Endocr Regul. 2022 Apr 30;56(2):148-162. doi: 10.2478/enr-2022-0016.
Rheumatoid arthritis is a common chronic inflammatory disease with substantial economic, social, and personal costs. Its pathogenesis is multifactorial and complex. The ultimate goal of rheumatoid arthritis treatment is stopping or slowing down the disease progression. In the past two decades, invention of new medicines, especially biologic agents, revolutionized the management of this disease. These agents have been associated with an improved prognosis and clinical remission, especially in patients who did not respond to traditional disease-modifying anti-rheumatic drugs (DMARDs). Improvement in the understanding of the rheumatoid arthritis pathogenesis leads to the development of novel biologic therapeutic approaches. In the present paper, we summarized the current therapeutics, especially biologic agents, available for the treatment of rheumatoid arthritis.
类风湿关节炎是一种常见的慢性炎症性疾病，具有巨大的经济、社会和个人负担。其发病机制是多因素和复杂的。类风湿关节炎治疗的最终目标是阻止或减缓疾病进展。在过去的二十年中，新药的发明，特别是生物制剂，彻底改变了这种疾病的治疗方法。这些药物与改善预后和临床缓解有关，特别是在那些对传统疾病修饰抗风湿药物（DMARDs）没有反应的患者中。对类风湿关节炎发病机制的认识的提高导致了新型生物治疗方法的发展。在本文中，我们总结了目前用于治疗类风湿关节炎的治疗方法，特别是生物制剂。
